Keio University Hospital treats cancer in central Tokyo.
It is best known for one thing. Some treatments look promising but are still being tested, so insurance does not pay for them yet. Japan has a national program that lets a few approved hospitals give those treatments anyway. Keio is approved for several of them. One of them uses the patient's own immune cells against cervical cancer. Immune cells are already inside the tumor, fighting it and losing. Doctors take some of those cells out and grow them in a laboratory until there are far more of them. The cells then go back into the patient, to attack the cancer they were already fighting. Keio is also approved for a blood test that looks for tiny pieces of tumor DNA after surgery. It can show that cancer is still there while scans still look clear. Two more treatments sit on the same list. One is keyhole surgery for cancer of the ovary. The other is a heavier dose schedule of temozolomide, the chemotherapy used against brain tumors called gliomas.
Background
Awards and recognition
Core Hospital for Cancer Genomic Medicine
Designated Cancer Care Hospital (Japan)
Regional Designated Cancer Care Hospital
Advanced Treatment Hospital (Tokutei Kino Byoin)
Founded by Shibasaburo Kitasato
We only show recognition from accrediting bodies, government agencies and major independent organizations. Paid or pay-to-display awards are never listed.
Treatment & Specialties
Keio is a general university hospital rather than a cancer-only center. A patient should understand what that means before the first visit. No single cancer department owns every case. Treatment lives in the clinical departments. A lymphoma belongs to hematology. A lung cancer belongs to pulmonary medicine and thoracic surgery. A stomach or colon cancer belongs to gastroenterology and the surgical departments. Urology, gynecology and pediatrics carry their own cancers as well. The arrangement puts real depth behind each disease site. The surgeon who operates has spent a career on that one organ. Its weakness is that a cancer needing three departments at once can fall between them. The Tumor Center exists to close that gap.
The Tumor Center was set up in 2009 and runs six units. The outpatient chemotherapy unit delivers drug treatment without admitting the patient. The radiation therapy unit covers the beam-based treatments. They damage the DNA of cells inside a targeted area so those cells cannot keep dividing. The palliative care unit manages pain and other symptoms alongside active treatment, rather than only at the end of it. A minimally invasive therapy development unit works on ways to reach a tumor without open surgery. The rehabilitation unit addresses the loss of strength and function that major surgery and long admissions cause. A cancer genomic medicine unit handles the gene testing of tumors. The center also hosts the hospital's oncology conferences. It reviews treatment protocols before they are used. That is the mechanism that keeps separate departments giving consistent care.
A distinctive part of what Keio offers is delivered under Japan's advanced medical care framework rather than routine insurance, and that has a financial consequence. Japan normally forbids mixing insured and uninsured treatment within one episode of care. This framework is one of the few exceptions. The routine parts of the admission stay on national insurance. The patient pays directly for the technique under evaluation. The results then feed the national decision on whether it should be covered in future. Keio's approvals include tumor-infiltrating lymphocyte therapy for cervical cancer. Those are immune cells taken from inside the tumor, grown in a laboratory and given back to the patient. The approvals also include keyhole surgery for cancer of the ovary. They include a dose-intensified schedule of temozolomide, a chemotherapy drug used against brain tumors. They include measurement of circulating tumor DNA, which means tiny pieces of tumor DNA floating in the blood. That test can show cancer left behind after treatment while scans still look clear. Japan runs a separate system called patient-proposed healthcare. It lets a patient start a request for a treatment not yet approved for their situation. Under that system Keio also offers targeted drug treatment guided by a gene panel that reads many genes at once.
Keio has been the Regional Designated Cancer Care Hospital for the Tokyo West district since 2011. It anchors cancer coordination for Shinjuku, Nakano and Suginami wards. The designation carries obligations rather than being a label. A designated hospital has to treat patients with teams that cross specialties. It has to provide palliative care. It has to keep a hospital-based cancer registry, a record of every cancer patient treated there. It also has to staff a consultation service open to patients who are not being treated there. Keio's Cancer Counseling and Support Center provides individual consultations. It holds patient salons twice a month. There is also a support team for adolescents and young adults. Treatment decisions for patients in their teens and twenties raise questions about preserving fertility and about education. A general cancer clinic is not built to answer those.
Keio received the Core Hospital designation in 2018, and the role comes with duties. Keio has to call together expert panels for a network of partner hospitals. It has to train the specialists that network needs. It also has to run genomic testing at a volume smaller hospitals cannot sustain. In 2024 it opened a Cancer Genomic Medicine Center. That center brings testing, treatment, research and training under one roof. The practical consequence reaches beyond Keio's own patients. Someone treated at a cooperating hospital in the network has their genomic report read by the panel that meets here. They do not have to transfer their care.
Keio is unusual in Japan because it develops its own genomic tests and offers them outside the insurance system. Insurance-covered panel testing is restricted to three groups. It covers cancers where nobody can find where the disease started. It covers rare cancers. It covers solid tumors after standard treatment has been exhausted. That leaves most patients with cancer ineligible. If the patient pays directly, more is available. There is a panel covering a few hundred genes. There is whole exome sequencing, which reads close to all 20,000 human genes rather than a preselected list. There is also a liquid biopsy, which screens for gene faults in a blood sample instead of a tissue sample. Whole exome sequencing can surface faults a fixed panel was never designed to look for. It also costs the patient directly. And it can return findings with no available treatment attached to them. That is a real consideration rather than a technicality.
The hospital's Center for Transfusion Medicine and Cell Therapy and its Cell Processing Center are what make cell-based treatment possible on site. Growing a patient's own immune cells to useful numbers requires a clean manufacturing facility under strict regulatory control. A hospital without one either ships cells elsewhere or cannot offer the treatment at all. That infrastructure sits behind Keio's tumor-infiltrating lymphocyte program. It works with the hospital's Clinical and Translational Research Center to move new cell-based immune treatments toward clinical use. The hospital also applies liquid biopsy to assess the risk of cancer returning after esophageal cancer surgery.
Cancer immunology at the affiliated Keio University School of Medicine should be read as separate from the hospital's clinical service. The faculty identified gut bacteria that enhance the activity of immune checkpoint inhibitors. Those drugs release a brake that cancers use to hide from the immune system. That is significant research in its own right. But it belongs to the medical school. It does not describe treatment a patient receives on the wards. What the hospital gains from sitting next to it is proximity. Findings can move into hospital-run trials quickly.
For International Patients
Japan's universal health insurance covers residents enrolled in the system. A visitor from abroad is not enrolled. Treatment is then billed on a self-pay basis, and the totals are set differently from what an insured patient pays. Costs should be confirmed in writing before any travel is booked.
Keio established an International Patient Services Department in 2023. It acts as the liaison between overseas patients and the clinical departments. It supports English and other languages inside the hospital. It also runs a lounge where patients from abroad and their families can wait before and after appointments. That is a genuine service. But it is a coordination function. It is not a separate international ward. The medical care itself happens in the ordinary clinical departments, alongside Japanese patients.
The hospital asks that a patient first consult a physician in their home country. You should arrive with recent records. That means the diagnosis, the treatment history, and the test and imaging data. Patients coming from abroad are directed to work through an accredited medical travel support company. They are not expected to contact the hospital themselves. Except in emergencies, allow at least two weeks for coordination. A complex case needing several departments will take longer than that.
The hospital is in Shinanomachi, Shinjuku City. It stands next to Shinanomachi station on the JR Chuo-Sobu line, a few stops from both Shinjuku and Tokyo stations. Tokyo is served by two international airports, Haneda and Narita.